Radiomics and circulating tumor cells: personalized care in hepatocellular carcinoma?

被引：15
作者：
Hesketh, Richard L. [1 ]
Zhu, Andrew X. [2 ]
Oklu, Rahmi [3 ]
机构：
[1] West Middlesex Univ Hosp, London, England
[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Hematol & Oncol, Boston, MA USA
[3] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Vasc Imaging & Intervent, Boston, MA 02130 USA
来源：
DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY | 2015年 / 21卷 / 01期
关键词：
GENE-EXPRESSION PROGRAMS; RECURRENT MUTATIONS; SOMATIC MUTATIONS; LIVER-CANCER; SERUM; MECHANISMS; SURVIVAL; IMPROVES;
D O I：
10.5152/dir.2014.14237
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Personalized care in oncology is expected to significantly improve morbidity and mortality, facilitated by our increasing understanding of the molecular mechanisms driving tumors and the ability to target those drivers. Hepatocellular carcinoma has a very high mortality to incidence ratio despite localized disease being curable, emphasizing the importance of early diagnosis. Radiomics, the use of imaging technology to extrapolate molecular tumor data, and the detection of circulating tumor cells (CTCs) are two new technologies that could be incorporated into the clinical setting with relative ease. Here we discuss the molecular mechanisms leading to the development of hepatocellular carcinoma focusing on the latest developments in liver magnetic resonance imaging, CTC, and radiomic technology and their potential to improve diagnosis, staging, and therapy.
引用
收藏
页码：78 / 84
页数：7
相关论文
共 49 条
[1]  
ABELEV GI, 1968, CANCER RES, V28, P1344
[2]   AFLATOXIN-B(1) INDUCES THE TRANSVERSION OF G-]T IN CODON 249 OF THE P53 TUMOR-SUPPRESSOR GENE IN HUMAN HEPATOCYTES [J].
AGUILAR, F ;
HUSSAIN, SP ;
CERUTTI, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (18) :8586-8590
[3]   Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma [J].
Arzumanyan, Alla ;
Reis, Helena M. G. P. V. ;
Feitelson, Mark A. .
NATURE REVIEWS CANCER, 2013, 13 (02) :123-135
[4]   The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website [J].
Bamford, S ;
Dawson, E ;
Forbes, S ;
Clements, J ;
Pettett, R ;
Dogan, A ;
Flanagan, A ;
Teague, J ;
Futreal, PA ;
Stratton, MR ;
Wooster, R .
BRITISH JOURNAL OF CANCER, 2004, 91 (02) :355-358
[5]   DEMONSTRATION OF A NEW PROTEIN FRACTION IN SERUM FROM THE HUMAN FETUS [J].
BERGSTRAND, CG ;
CZAR, B .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 1956, 8 (02) :174-174
[6]   Pinched flow coupled shear-modulated inertial microfluidics for high-throughput rare blood cell separation [J].
Bhagat, Ali Asgar S. ;
Hou, Han Wei ;
Li, Leon D. ;
Lim, Chwee Teck ;
Han, Jongyoon .
LAB ON A CHIP, 2011, 11 (11) :1870-1878
[7]   Management of Hepatocellular Carcinoma: An Update [J].
Bruix, Jordi ;
Sherman, Morris .
HEPATOLOGY, 2011, 53 (03) :1020-1022
[8]  
BUTLER TP, 1975, CANCER RES, V35, P512
[9]   Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties [J].
Coulouarn, C. ;
Factor, V. M. ;
Andersen, J. B. ;
Durkin, M. E. ;
Thorgeirsson, S. S. .
ONCOGENE, 2009, 28 (40) :3526-3536
[10]   Use of Surveillance for Hepatocellular Carcinoma Among Patients With Cirrhosis in the United States [J].
Davila, Jessica A. ;
Morgan, Robert O. ;
Richardson, Peter A. ;
Du, Xianglin L. ;
McGlynn, Katherine A. ;
El-Serag, Hashem B. .
HEPATOLOGY, 2010, 52 (01) :132-141
12345